Skip to main content
OpenTrials
Completed

NCT Number: NCT03052621

Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer

Locally advance breast cancer and extensive locoregional recurrence are still considered as complexity of reconstruction. Although previous studies concluded that omental transposition was considerably indicated in poor vascularity in irradiated tissue, secondary infection and large defect become the obstacles of local tissue flaps. While some centres showed the excellent healing of omental transposition. Meanwhile, many studies showed the preferable outcome in escalating radiotherapy in term of locoregional control. In the investigators' institute, omental transposition in breast cancer has been developed for twenty years. The only institute in Thailand enhanced using this procedure in order to closure of large primary breast cancer and chest wall recurrence. This procedure is undertaken by single surgeon (Dr. K.J.). The investigators' protocol of omental transposition is including preoperative chemotherapy, preoperative accelerated radiation up to 80 Gy, approval of breast cancer centre committee, and meticulous wound care including vacuum assisted wound dressing, non-adhesive dressing. As a result, survival time could be improved.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Queen Sirikit Centre for Breast Cancer

Bangkok, 10330, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patients with omental transposition operation within King Chulalongkorn Memorial Hospital
  • More than 18 years of age

Exclusion criteria

  • The patients with refusal

Treatment and study plan

Omental transposition

Procedure

Harvesting the omentum to cover irradiated defects of breast cancer

Other names: Omental graft

Primary outcomes

  1. Survival time

    Time frame: 22 years

Sponsors and collaborators

Lead sponsor

Queen Sirikit Centre for Breast Cancer

Other

Registry information

Important dates

Study start
1994
Primary completion
2016
Study completion
2016
First posted
Feb 14, 2017
Registry last updated
Feb 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.